Rezolute AI Stock Analysis
Rezolute (6HV1) AI Stock Analysis
Rezolute
(Frankfurt:6HV1)
No summary available
Rezolute (6HV1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 353.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 426
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 1.03
- Revenue Growth
- ―
- EPS Growth
- 23.90%
- Country
- Germany
- Employees
- 63
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Rezolute Business Overview & Revenue Model
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...
Rezolute Risk Analysis
Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskRezolute Peers Comparison
Overall Rating
ABUS70Outperform
XNCR61Neutral
TSHA54Neutral
GERN51Neutral
KOD50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | $626.97M | 3.62 | 129.13% | ― | 1142.57% | ― | |
| 61Neutral | $2.78B | -23.62 | -21.29% | ― | 33.55% | 11.51% | |
| 54Neutral | $1.34B | -9.53 | -51.87% | ― | -13.07% | -23.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $622.98M | -13.79 | -22.27% | ― | 18.60% | 37.60% | |
| 50Neutral | $7.27B | -27.25 | -287.64% | ― | ― | 0.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6HV1 | Rezolute, Inc. | 3.74 | -4.86 | -56.51% | |
| GERN | Geron Corporation | 0.97 | -0.16 | -14.42% | |
| ABUS | Arbutus Biopharma | 4.09 | -0.45 | -9.91% | |
| XNCR | Xencor Inc. | 37.09 | 21.47 | 137.45% | |
| KOD | Kodiak Sciences | 111.19 | 91.36 | 460.72% | |
| TSHA | Taysha Gene Therapies, Inc. | 4.10 | -0.02 | -0.49% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
